SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Alan Turing — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAlan Turing
Date of birth1912-06-23
IdentifiersMRN HR-ML007-SYN-TD; SSN (made up) 000-07-6290
Document date1953-04-28
AuthorRupert Hallam, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week follow-up; endocrinology consultation and scrotal ultrasound today. [S]

History of Present Illness

Mr. Turing returns two weeks after his first visit, five weeks after the last estrogen injection. He saw Dr. Montrose-Adeyemi of endocrinology this morning and had a scrotal ultrasound, which was normal. His breasts are still tender against his shirt, with no change in size, and he has had no nipple discharge. Libido and morning erections are still absent. He has had two sessions with the clinic psychologist and found them easier than he expected; they have begun with what was done to him rather than with his sexuality, which he says he has never regarded as the problem. He sleeps five to six hours and has run twice this week, alone. He has had no suicidal thoughts and keeps his safety plan on his phone. He takes cholecalciferol daily. [S]

ElementDetail
BreastsStill tender; no change in size; no discharge
Sexual functionLibido and morning erections still absent
PsychotherapyTwo sessions with the clinic psychologist
Sleep and activityFive to six hours; ran twice this week
SafetyNo suicidal thoughts since intake; safety plan on his phone
PHQ-914, down from 15

Review of Systems

SystemResultFinding
BreastPositiveTender breast tissue on both sides; no discharge or new lump
GenitourinaryPositiveLow libido and no morning erections; no testicular pain or swelling
CardiovascularNegativeNo leg swelling or calf pain
PsychiatricPositiveLow mood and interest, poor sleep; no suicidal thoughts, elevated mood, or racing thoughts

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1953-04-14activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1953-04-28Body height178cmS
1953-04-28Body weight71kgS
1953-04-28Body mass index (BMI) [Ratio]22.4kg/m2S
1953-04-28Systolic blood pressure120mm[Hg]S
1953-04-28Diastolic blood pressure74mm[Hg]S
1953-04-28Heart rate62/minS
1953-04-28Respiratory rate14/minS
1953-04-28Body temperature36.5CelS
1953-04-28Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1953-04-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]14{score}S
1953-04-28Estradiol (E2) [Mass/volume] in Serum or Plasma46pg/mL7.6-42.6 pg/mLHighS
1953-04-28Lutropin [Units/volume] in Serum or Plasma0.9m[IU]/mL1.7-8.6 m[IU]/mLLowS

Physical Exam

Vital signs recorded on 1953-04-28; see the Vital Signs section. [S]

SystemFinding
GeneralTall, lean, tired
BreastExamined with his agreement and a chaperone offered and declined: firm, tender, rubbery disc of glandular tissue about 4 cm across behind each nipple, centered and symmetric; no discrete or eccentric mass, skin change, nipple discharge, or axillary nodes
GenitourinaryExamined with his agreement: testes soft and slightly small, without masses, as the ultrasound confirmed
Mental statusAlert and cooperative; mood "still flat"; affect constricted but brightens on his work; thought process linear; no suicidal ideation; no psychotic features; insight and judgment good

Problems

ProblemClinical statusVerificationCodeProvenance
Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatmentactiveconfirmed N62S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic.
Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigueactiveconfirmed E23.1S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops.
Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonmentactiveconfirmed T38.5X5AS — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm.
Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime)activeconfirmed F32.1S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R).
Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)activeconfirmed E55.9S — Synthetic finding of the bone-health workup.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBreast examination for size, tenderness, and any discrete massEvery visit until the gynecomastia settlesCompleted todayFirm, tender glandular tissue about 4 cm behind each nipple; symmetric; no discrete mass, skin change, discharge, or nodes
ImagingBreast ultrasound or mammographyOnly if the examination is equivocal or a discrete mass is feltNot indicatedTypical bilateral, centered gynecomastia on examination
ImagingScrotal ultrasoundOnce, in the gynecomastia workupCompleted todayTestes about 15 mL each, homogeneous; no mass; no varicocele
LaboratoryEstradiol and LH while the estrogen clearsEvery 6 to 8 weeks after the exposure stops, until normalCompleted todayEstradiol 46 pg/mL, down from 148; LH 0.9 mIU/mL, still suppressed
LaboratoryhCG, AFP, liver, kidney, and thyroid testsOnce, at the initial workupUp to dateAll normal at intake two weeks ago
Medication safetyTestosterone therapyOnly for persistent, symptomatic, confirmed testosterone deficiencyNot indicatedNot given while the axis recovers: it would suppress LH and FSH again and is not indicated for a transient, drug-induced low testosterone
ReferralEndocrinology consultationFor gynecomastia with abnormal hormone resultsCompleted todaySeen today; drug-induced cause confirmed; recovery monitoring agreed
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today14, down from 15 at intake
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior since intake; PHQ-9 item 9 scored 0. Protective factors unchanged. Safety plan reviewed: on his phone, with 988 and the clinic number
SurveyBipolar screen at the initial workupOnce, at the initial depression workupCompleted todayInterview found no past manic or hypomanic episode and no family history known to him; no Mood Disorder Questionnaire score is recorded
Self-managementPsychotherapy, sleep, running, and social contactEvery visit during active treatmentCompleted todayTwo sessions with a gay-affirming psychologist; sleep five to six hours; two runs alone
LaboratoryLithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS)Only on those drugsNot indicatedNot on any of these drugs

Goal progress:

Guideline basis: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Review in six weeks with hormone tests and PHQ-9. Next scheduled visit 1953-06-09: eight-week review of hormone recovery and depression treatment. [S]